

Special Issue

Novel Biomarkers in Leukemia: From Benchtop to Bedside

Message from the Guest Editors

Leukemia is a highly heterogeneous disease caused by the malignant transformation of undifferentiated myeloid/lymphoid hematopoietic progenitors.

The identification of new leukemia biomarkers represents a crucial step for diagnosis, prognosis and treatment. Currently, cytogenetic markers are widely used for diagnosis and patient stratification. However, the situation is rapidly changing due to the application of other methodologies based on the characterization of disease-causing mutations and of epigenetic and proteomic profiles. In this Special Issue, we are inviting the submission of reviews and novel research results in the field. In this Special Issue, special attention will be given to manuscripts highlighting the interplay between the search for new biomarkers and the elucidation of the molecular basis of this widespread disease. Moreover, articles dealing with identifying surface antigens in leukemia to plan novel CAR-T-mediated cellular therapy will be welcome.

Guest Editors

Dr. Peppino Mirabelli

Dr. Luigi Vitagliano

Dr. Giovanni Smaldone

Deadline for manuscript submissions

closed (30 September 2022)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/115096

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).